## **David Peace**

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10157780/publications.pdf

Version: 2024-02-01

1937685 1720034 9 184 4 7 citations h-index g-index papers 9 9 9 279 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. Journal of Clinical Oncology, 2020, 38, 2519-2529.	1.6	93
2	Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). Journal of Clinical Oncology, 2022, 40, 2913-2923.	1.6	40
3	Burkitt Lymphoma International Prognostic Index. Journal of Clinical Oncology, 2021, 39, 1129-1138.	1.6	37
4	Long-term survival consequent on the abscopal effect in a patient with multiple myeloma. BMJ Case Reports, 2016, 2016, bcr2016215237.	0.5	7
5	Race/ethnicity and underlying disease influences hematopoietic stem/progenitor cell mobilization response: A single center experience. Journal of Clinical Apheresis, 2021, 36, 634-644.	1.3	3
6	Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers. Blood, 2018, 132, 451-451.	1.4	3
7	Health Care Utilization in Transplanted Versus Non-Transplanted Sickle Cell Disease Patients. Blood, 2018, 132, 313-313.	1.4	1
8	A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients. Blood, 2018, 132, 5218-5218.	1.4	0
9	The Burkitt Lymphoma International Prognostic Index (BL-IPI). Blood, 2020, 136, 46-49.	1.4	O